Due to the activity of WB156 on a limited number of leukemia cells, Tang et al. explored the creation of a new class of PROTAC–MDM2 degraders derived from another class of known MDM2 inhibitors, which could be diversified by a four-component Ugi reaction. The gene discussed is MDM2; the disease is leukemia.